



UNITED STATES DEPARTMENT OF COMMERCE **United States Patent and Trademark Office**

Address: COMMISSIONER OF PATENTS AND TRADEMARKS

Washington, D.C. 20231

ATTORNEY DOCKET NO. FIRST NAMED INVENTOR FILING DATE APPLICATION NO. 10/20/99 GAGE

HM12/0508

STEPHEN E REITER GRAY CARY WARE & FREIDENRICH LLP 4365 EXECUTIVE DRIVE **SUITE 1600** SAN DIEGO CA 92121

09/421,971

ļ: 	SALK2350	
EXAMINER		
MURPHY.	T PAPER NUMBER	
AMTUNIT	C	
1646 DATE MAILED:		
	05/08/01	

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

1		Application No.	Applicant(s)	
Office Action Summary	09/421,971	GAGE ET AL.		
	Examiner	Art Unit		
	Joseph F Murphy	1646		
 Period fo	- The MAILING DATE of this communication appe or Reply	ars on the cover sheet with the co	rrespondence address	
THE I - Exter after - If the - If NO - Failu - Any r	ORTENED STATUTORY PERIOD FOR REPLY MAILING DATE OF THIS COMMUNICATION. nsions of time may be available under the provisions of 37 CFR 1.13 SIX (6) MONTHS from the mailing date of this communication. period for reply specified above is less than thirty (30) days, a reply period for reply is specified above, the maximum statutory period we to reply within the set or extended period for reply will, by statute, eply received by the Office later than three months after the mailing ad patent term adjustment. See 37 CFR 1.704(b).	66 (a). In no event, however, may a reply be tinwithin the statutory minimum of thirty (30) days ill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	nely filed s will be considered timely. the mailing date of this communication. D (35 U.S.C. § 133).	
1)🖂	Responsive to communication(s) filed on 20 C	October 1999 .	•	
2a)□	This action is FINAL . 2b)⊠ Thi	s action is non-final.		
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.				
Dispositi	on of Claims			
4)🖂	Claim(s) $\underline{1-60}$ is/are pending in the application			
	4a) Of the above claim(s) is/are withdraw	vn from consideration.		
5)	Claim(s) is/are allowed.		•	
6)	Claim(s) is/are rejected.			
7)	Claim(s) is/are objected to.			
8)🛛	Claims <u>1-60</u> are subject to restriction and/or e	lection requirement.		
Applicati	on Papers			
9)	The specification is objected to by the Examine	er.		
10)	The drawing(s) filed on is/are objected to	o by the Examiner.		
11) The proposed drawing correction filed on is: a) □ approved b) □ disapproved.				
12) The oath or declaration is objected to by the Examiner.				
Priority ι	ınder 35 U.S.C. ≬ 11 9			
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).				
a) All b) Some * c) None of:				
1. Certified copies of the priority documents have been received.				
2. Certified copies of the priority documents have been received in Application No				
3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received.				
14) Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e).				
Attachmen		10\ 🗀 اسلمستامی ۵۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰	ni (PTO 413) Ponor No/o\	
16) 🔲 Not	ice of References Cited (PTO-892) ice of Draftsperson's Patent Drawing Review (PTO-948) rmation Disclosure Statement(s) (PTO-1449) Paper No(s) _	19) Notice of Informal	ry (PTO-413) Paper No(s) Patent Application (PTO-152) Sheet; Notice to Comply .	

Art Unit: 1646

DETAILED ACTION

Please Note: In an effort to enhance communication with our customers and reduce processing time, Group 1640 is running a Fax Response Program for Written Restriction Requirements. A dedicated Fax machine is in place to receive your responses. The Fax number is 703-305-3704. A Fax cover sheet is attached to this Office Action for your convenience. We encourage your participation in this Program. If you have any questions or suggestions please contact Paula Hutzell, Ph.D., Supervisory Patent Examiner at Paula.Hutzell@uspto.gov or 703-308-4310. Thank you in advance for allowing us to enhance our customer service. Please limit the use of this dedicated Fax number to responses to Written Restrictions.

Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. Claims 1-22, 52-54, drawn to a chimeric protein, classified in class 530, subclass 350.
- II. Claims 23-25, drawn to a polynucleotide and a host cell, classified in class 536, subclass 23.5.
- III. Claims 26-32, drawn to a method for modulating the expression of an exogenous gene in an organism, classified in class 514, subclass 2.
- IIII. Claims 33-39, 43-51, drawn to a method for modulating the expression of an exogenous gene in an organism containing a DNA construct, classified in class 800, subclass 3.
- V. Claims 40-42, drawn to a method for modulating the expression of an exogenous gene in a cell containing a DNA construct, classified in class 424, subclass 192.1.
- VI. Claims 55-56, drawn to a set of x-ray diffraction coordinates, unclassifiable.

Art Unit: 1646

VII. Claims 57-60, drawn to a method of compound identification, classified in class 435, subclass 7.8.

The inventions are distinct, each from the other because of the following reasons:

Inventions I-II, VI are independent and distinct, each from the other, because they are products which possess characteristic differences in structure and function, and each has an independent utility, that is distinct for each invention which cannot be exchanged.

Inventions III-V, VII are independent and distinct, each from the other, because the methods are practiced with materially different starting materials, have materially different purposes steps, and are for materially different purposes.

Inventions I and III-V are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the protein of invention I can be used for the production of antibodies.

Invention II is unrelated to inventions III-V and VII. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions are not disclosed as capable of use together.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter and separate classification, restriction for examination purposes as indicated is proper.

Art Unit: 1646

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Sequence Rules

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures.

Art Unit: 1646

Advisory Information

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Joseph F. Murphy whose telephone number is 703-305-7245. The examiner can normally be reached on M-F 7:30-5:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Yvonne Eyler can be reached on 703-308-6564. The fax phone numbers for the organization where this application or proceeding is assigned are 703-305-3014 for regular communications and 703-308-0294 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-0196.

Joseph F. Murphy, Ph. D.

Patent Examiner Art Unit 1646

May 1, 2001

PREMA MERTZ
PRIMARY EXAMINER

Application No.: 07/1/174

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
7. Other:
Applicant Must Provide:
An <u>initial</u> or substitute computer readable form (CRF) copy of the "Sequence Listing".
An <u>initial</u> or substitute paper copy of the "Sequence Listing", as well as an amendment directing its ent into the specification.
A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).
For exections regarding compliance to these requirements, please contact:

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

For Patentin software help, call (703) 308-6856

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE



RESTRICTION ELECTION **FACSIMILE** TRANSMISSION

DATE:
FROM/ATTORNEY:
FIRM:
PAGES, INCLUDING COVERSHEET:
PHONE NUMBER:
TO EXAMINER:
ART UNIT:
SERIAL NUMBER:
FAX/TELECOPIER NUMBER: (703) 305-3704
PLEASE NOTE: THIS FACSIMILE NUMBER IS TO BE USED ONLY FOR RESPONSES TO RESTRICTIONS.
COMMENTS:
TE YOU HAVE NOT RECEIVED ALL THE PAGES OF THIS TRANSMISSION, PLEASE CONTACT THE ATTORNEY AT THE

IF YOU HAVE NOT RECEIVED ALL THE PAGES OF TELEPHONE NUMBER LISTED ABOVE.

IN COMPLIANCE WITH 1096 OG 30, THE FILING DATE ACCORDED EACH OFFICIAL FAX TRANSMISSION WILL BE DETERMINED BY THE FAX MACHINE DATE STAMP FOUND ON THE LAST PAGE OF THE TRANSMISSION, UNLESS THAT DATE IS A SATURDAY, SUNDAY, OR FEDERAL HOLIDAY WITHIN THE DISTRICT OF COLUMBIA, IN WHICH CASE THE OFFICIAL DATE OF RECEIPT WILL BE THE NEXT BUSINESS DAY.

THE DOCUMENT(S) ACCOMPANYING THIS FACSIMILE TRANSMISSION CONTAIN(S) INFORMATION FROM THE UNITED STATES PATENT AND TRADEMARK OFFICE WHICH IS CONFIDENTIAL AND/OR LEGALLY PRIVILEGED. THIS INFORMATION IS FOR THE USE OF THE INDIVIDUAL OR FIRM NAMED ON THIS SHEET. IF YOU ARE NOT THE INTENDED RECIPIENT, YOU ARE HEREBY NOTIFIED THAT ANY DISCLOSURE, COPYING, DISTRIBUTION, OR THE TAKING OF ANY ACTION IN RELIANCE ON THE CONTENTS OF THIS INFORMATION IS STRICTLY PROHIBITED. THE DOCUMENTS SHOULD BE RETURNED TO THE PATENT AND TRADEMARK OFFICE IMMEDIATELY. IF THIS FACSIMILE IS RECEIVED IN ERROR, PLEASE NOTIFY THE ATTORNEY LISTED HEREON IMMEDIATELY.